- Home
- WERN vs PGEN Comparison
WERN vs PGEN Comparison
Compare WERN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | PGEN |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WERN | PGEN |
|---|---|---|
| Price | $33.56 | $4.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $31.07 | $8.33 |
| AVG Volume (30 Days) | 853.8K | ★ 5.5M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,974,396,000.00 | $230,981,000.00 |
| Revenue This Year | $21.27 | $1,115.92 |
| Revenue Next Year | $6.71 | $81.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.02 | $1.23 |
| 52 Week High | $38.45 | $5.47 |
Technical Indicators
Market Signals| Indicator | WERN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.12 | 56.19 |
| Support Level | $31.85 | $4.02 |
| Resistance Level | $35.39 | $4.43 |
| Average True Range (ATR) | 1.16 | 0.28 |
| MACD | 0.41 | 0.02 |
| Stochastic Oscillator | 96.61 | 76.85 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.